News
The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...
In turn, while the overall impact from them is still yet to be seen, Mr Bailey says tightening rates further could be more ...
AstraZeneca’s chief executive has discussed quitting Britain in a move that would deal a significant blow to the City of ...
London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca ...
AstraZeneca is reportedly considering moving its listing to the US. Here's why AZN's expected departure is alarming for the ...
AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...
Reports are circulating that AstraZeneca shares could be moving off the London exchange with its CEO favouring a US market ...
London's IPO drought just hit a new lowand it's getting harder to ignore. AstraZeneca (NASDAQ:AZN), the UK's largest listed ...
Suggestions that AstraZeneca might cross the Atlantic should act as a huge wake-up call.
The boss of Britain’s most valuable company, Astrazeneca, has reportedly voiced his preference to move the firm’s stock ...
1d
GlobalData on MSNAstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancerThe approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.
Pressure is piling on London's stock exchange, with reports that British pharma giant AstraZeneca may move its listing to the U.S. delivering yet another blow this week. Stream Connecticut News ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results